THRX-198321 Is a bifunctional muscarinic receptor antagonist and β2-adrenoceptor agonist (MABA) that binds in a bimodal and multivalent manner

Molecular Pharmacology

Volumn 79, Issue 3, 2011, Pages 389-399

  Steinfeld, Tod ^a   Hughes, Adam D ^a   Klein, Uwe ^a   Smith, Jacqueline A M ^a   Mammen, Mathai ^a  

^a THERAVANCE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ATROPINE; BETA 2 ADRENERGIC RECEPTOR; BIPHENYL 2 YLCARBAMIC ACID 1 [9 [2 HYDROXY 2 (8 HYDROXY 2 OXO 1,2 DIHYDROQUINOLIN 5 YL)ETHYLAMINO]NONYL]PIPERIDIN 4 YL ESTER; BIPHENYL CARBAMIC ACID PIPERIDINYL ESTER; CARBAMIC ACID; ESTER DERIVATIVE; ISOPRENALINE; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; OBIDOXIME; OXOTREMORINE; PROPRANOLOL; RADIOLIGAND; THRX 198321; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL AGGREGATION; CONCENTRATION RESPONSE; DISSOCIATION; DRUG ACTIVITY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ANIMALS; BINDING SITES; BINDING, COMPETITIVE; CARBAMATES; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIC AMP; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); INOSITOL PHOSPHATES; MUSCARINIC AGONISTS; PHARMACOKINETICS; QUINOLONES; RADIOLIGAND ASSAY;

EID: 79951997039     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.110.069120     Document Type: Article

References (36)

1. Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O'Donnell D, McIvor A, Sharma S, et al. (2007) Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 146:545-555. (Pubitemid 351650535)
2. Antony J, Kellershohn K, Mohr-Andrä M, Kebig A, Prilla S, Muth M, Heller E, Disingrini T, Dallanoce C, Bertoni S, et al. (2009) Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity. FASEB J 23:442-450.
3. Arch JR, Ainsworth AT, Cawthorne MA, Piercy V, Sennitt MV, Thody VE, Wilson C, and Wilson S (1984) Atypical beta-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature 309:163-165. (Pubitemid 14142787)
4. Arunlakshana O and Schild HO (1959) Some quantitative uses of drug antagonists. Br J Pharmacol Chemother 14:48-58.
5. Baker WL, Baker EL, and Coleman CI (2009) Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis. Pharmacotherapy 29:891-905.
6. Baloira Villar A and Vilariño Pombo C (2005) [Bronchodilator efficacy of combined salmeterol and tiotropium in patients with chronic obstructive pulmonary disease]. Arch Bronconeumol 41:130-134.
7. Calverley PM (2004) Reducing the frequency and severity of exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 1:121-124.
8. Cazzola M, Centanni S, Santus P, Verga M, Mondoni M, di Marco F, and Matera MG (2004) The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir Med 98:1214-1221. (Pubitemid 39497224)
9. Cheng Y and Prusoff WH (1973) relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
10. Disingrini T, Muth M, Dallanoce C, Barocelli E, Bertoni S, Kellershohn K, Mohr K, De Amici M, and Holzgrabe U (2006) Design, synthesis, and action of oxotremorine-related hybrid-type allosteric modulators of muscarinic acetylcholine receptors. J Med Chem 49:366-372.
11. Ellis J and Seidenberg M (1992) Two allosteric modulators interact at a common site on cardiac muscarinic receptors. Mol Pharmacol 42:638-641. (Pubitemid 23027627)
12. Green SA, Spasoff AP, Coleman RA, Johnson M, and Liggett SB (1996) Sustained activation of a G protein-coupled receptor via "anchored" agonist binding. Molecular localization of the salmeterol exosite within the 2-adrenergic receptor. J Biol Chem 271:24029-24035.
13. Griffin JH, Linsell MS, Nodwell MB, Chen Q, Pace JL, Quast KL, Krause KM, Farrington L, Wu TX, Higgins DL, et al. (2003) Multivalent drug design. Synthesis and in vitro analysis of an array of vancomycin dimers. J Am Chem Soc 125:6517-6531. (Pubitemid 36605420)
14. Kebig A, Kostenis E, Mohr K, and Mohr-Andrä M (2009) An optical dynamic mass redistribution assay reveals biased signaling of dualsteric GPCR activators. J Recept Signal Transduct Res 29:140-145.
15. Leff P and Dougall IG (1993) Further concerns over Cheng-Prusoff analysis. Trends Pharmacol Sci 14:110-112. (Pubitemid 23113114)
16. Lew MJ and Angus JA (1995) Analysis of competitive agonist-antagonist interactions by nonlinear regression. Trends Pharmacol Sci 16:328-337.
17. Long DD, Aggen JB, Christensen BG, Judice JK, Hegde SS, Kaniga K, Krause KM, Linsell MS, Moran EJ, and Pace JL (2008) A multivalent approach to drug discovery for novel antibiotics. J Antibiot (Tokyo) 61:595-602.
18. Mammen M, Choi SK, and Whitesides GM (1998a) Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew Chem Int Ed 37:2754-2794. (Pubitemid 29008561)
19. Mammen M, Shakhnovich EI, and Whitesides GM (1998b) Using a convenient, quantitative model for torsional entropy to establish qualitative trends for molecular processes that restrict conformational freedom. J Org Chem 63:3168-3175. (Pubitemid 128500459)
20. Mathers CD and Loncar D (2006) Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3:e442.
21. May LT, Leach K, Sexton PM, and Christopoulos A (2007) Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 47:1-51. (Pubitemid 46277033)
22. McKinnell RM, Armstrong SR, Beattie DT, Choi SK, Fatheree PR, Gendron RA, Goldblum A, Humphrey PP, Long DD, Marquess DG, et al. (2009) A multivalent approach to the design and discovery of orally efficacious 5-HT4 receptor agonists. J Med Chem 52:5330-5343.
23. Milecki J, Baker SP, Standifer KM, Ishizu T, Chida Y, Kusiak JW, and Pitha J (1987) Carbostyril derivatives having potent beta-adrenergic agonist properties. J Med Chem 30:1563-1566.
24. Naito R, Takeuchi M, Morihira K, Hayakawa M, Ikeda K, Shibanuma T, and Isomura Y (1998a) Selective muscarinic antagonists. I. Synthesis and antimuscarinic properties of 4-piperidyl benzhydrylcarbamate derivatives. Chem Pharm Bull (Tokyo) 46:1274-1285. (Pubitemid 28407257)
25. Naito R, Takeuchi M, Morihira K, Hayakawa M, Ikeda K, Shibanuma T, and Isomura Y (1998b) Selective muscarinic antagonists. II. Synthesis and antimuscarinic properties of biphenylylcarbamate derivatives. Chem Pharm Bull (Tokyo) 46:1286-1294. (Pubitemid 28407258)
26. Smith C and Teitler M (1999) Beta-blocker selectivity at cloned human beta 1- and beta 2-adrenergic receptors. Cardiovasc Drugs Ther 13:123-126. (Pubitemid 29224837)
27. Smith JA, Amagasu SM, Hembrador J, Axt S, Chang R, Church T, Gee C, Jacobsen JR, Jenkins T, Kaufman E, et al. (2006) Evidence for a multivalent interaction of symmetrical, N-linked, lidocaine dimers with voltage-gated Na+ channels. Mol Pharmacol 69:921-931. (Pubitemid 43363866)
28. Steinfeld T, Mammen M, Smith JA, Wilson RD, and Jasper JR (2007) A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor. Mol Pharmacol 72:291-302. (Pubitemid 47124109)
29. 2+ on the beta2 adrenergic receptor. J Biol Chem 278:352-356.
30. 2+. Mol Pharmacol 61:65-72.
31. Tashkin DP, Littner M, Andrews CP, Tomlinson L, Rinehart M, and Denis-Mize K (2008) Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir Med 102:479-487.
32. Tränkle C and Mohr K (1997) Divergent modes of action among cationic allosteric modulators of muscarinic M2 receptors. Mol Pharmacol 51:674-682. (Pubitemid 27172996)
33. Valant C, Gregory KJ, Hall NE, Scammells PJ, Lew MJ, Sexton PM, and Christopoulos A (2008) A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand. J Biol Chem 283:29312-29321.
34. van Noord JA, Aumann JL, Janssens E, Smeets JJ, Verhaert J, Disse B, Mueller A, and Cornelissen PJ (2005) Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 26:214-222. (Pubitemid 41079064)
35. van Noord JA, Aumann JL, Janssens E, Verhaert J, Smeets JJ, Mueller A, and Cornelissen PJ (2006) Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 129:509-517.
36. Yoshizaki S, Tanimura K, Tamada S, Yabuuchi Y, and Nakagawa K (1976) Sympathomimetic amines having a carbostyril nucleus. J Med Chem 19:1138-1142.